Skip to main content

Advertising Disclaimer »

Main menu

  • Journals
    • Pediatrics
    • Hospital Pediatrics
    • Pediatrics in Review
    • NeoReviews
    • AAP Grand Rounds
    • AAP News
  • Authors/Reviewers
    • Submit Manuscript
    • Author Guidelines
    • Reviewer Guidelines
    • Open Access
    • Editorial Policies
  • Content
    • Current Issue
    • Online First
    • Archive
    • Blogs
    • Topic/Program Collections
    • AAP Meeting Abstracts
  • Pediatric Collections
    • COVID-19
    • Racism and Its Effects on Pediatric Health
    • More Collections...
  • AAP Policy
  • Supplements
  • Multimedia
    • Video Abstracts
    • Pediatrics On Call Podcast
  • Subscribe
  • Alerts
  • Careers
  • Other Publications
    • American Academy of Pediatrics

User menu

  • Log in
  • My Cart

Search

  • Advanced search
American Academy of Pediatrics

AAP Gateway

Advanced Search

AAP Logo

  • Log in
  • My Cart
  • Journals
    • Pediatrics
    • Hospital Pediatrics
    • Pediatrics in Review
    • NeoReviews
    • AAP Grand Rounds
    • AAP News
  • Authors/Reviewers
    • Submit Manuscript
    • Author Guidelines
    • Reviewer Guidelines
    • Open Access
    • Editorial Policies
  • Content
    • Current Issue
    • Online First
    • Archive
    • Blogs
    • Topic/Program Collections
    • AAP Meeting Abstracts
  • Pediatric Collections
    • COVID-19
    • Racism and Its Effects on Pediatric Health
    • More Collections...
  • AAP Policy
  • Supplements
  • Multimedia
    • Video Abstracts
    • Pediatrics On Call Podcast
  • Subscribe
  • Alerts
  • Careers

Discover Pediatric Collections on COVID-19 and Racism and Its Effects on Pediatric Health

American Academy of Pediatrics
Article

Antibiotic Exposure and Juvenile Idiopathic Arthritis: A Case–Control Study

Daniel B. Horton, Frank I. Scott, Kevin Haynes, Mary E. Putt, Carlos D. Rose, James D. Lewis and Brian L. Strom
Pediatrics August 2015, 136 (2) e333-e343; DOI: https://doi.org/10.1542/peds.2015-0036
Daniel B. Horton
aCenter for Clinical Epidemiology and Biostatistics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania;
bDivision of Rheumatology, Nemours/Alfred I. duPont Hospital for Children, Wilmington, Delaware;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Frank I. Scott
aCenter for Clinical Epidemiology and Biostatistics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania;
cDivision of Gastroenterology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kevin Haynes
aCenter for Clinical Epidemiology and Biostatistics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania;
dClinical Epidemiology, HealthCore, Wilmington, Delaware; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mary E. Putt
aCenter for Clinical Epidemiology and Biostatistics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carlos D. Rose
bDivision of Rheumatology, Nemours/Alfred I. duPont Hospital for Children, Wilmington, Delaware;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James D. Lewis
aCenter for Clinical Epidemiology and Biostatistics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania;
cDivision of Gastroenterology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brian L. Strom
aCenter for Clinical Epidemiology and Biostatistics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania;
eRutgers Biomedical and Health Sciences, New Brunswick, New Jersey
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • Comments
Loading
Download PDF

Abstract

BACKGROUND AND OBJECTIVE: Recent evidence has linked childhood antibiotic use and microbiome disturbance to autoimmune conditions. This study tested the hypothesis that antibiotic exposure was associated with newly diagnosed juvenile idiopathic arthritis (JIA).

METHODS: We performed a nested case–control study in a population-representative medical records database from the United Kingdom. Children with newly diagnosed JIA were compared with age- and gender-matched control subjects randomly selected from general practices containing at least 1 case, excluding those with inflammatory bowel disease, immunodeficiency, or other systemic rheumatic diseases. Conditional logistic regression was used to examine the association between antibacterial antibiotics (including number of antibiotic courses and timing) and JIA after adjusting for significant confounders.

RESULTS: Any antibiotic exposure was associated with an increased rate of developing JIA (adjusted odds ratio: 2.1 [95% confidence interval: 1.2–3.5]). This relationship was dose dependent (adjusted odds ratio over 5 antibiotic courses: 3.0 [95% confidence interval: 1.6–5.6]), strongest for exposures within 1 year of diagnosis, and did not substantively change when adjusting for number or type of infections. In contrast, nonbacterial antimicrobial agents (eg, antifungal, antiviral) were not associated with JIA. In addition, antibiotic-treated upper respiratory tract infections were more strongly associated with JIA than untreated upper respiratory tract infections.

CONCLUSIONS: Antibiotics were associated with newly diagnosed JIA in a dose- and time-dependent fashion in a large pediatric population. Antibiotic exposure may play a role in JIA pathogenesis, perhaps mediated through alterations in the microbiome.

  • Abbreviations:
    CI —
    confidence interval
    IBD —
    inflammatory bowel disease
    JIA —
    juvenile idiopathic arthritis
    OR —
    odds ratio
    THIN —
    The Health Improvement Network
    URI —
    upper respiratory tract infection
  • What’s Known on This Subject:

    The etiology of juvenile idiopathic arthritis (JIA) is poorly understood. A recent study suggested a link between antibiotics and JIA but did not examine the potential for confounding from infections or the role of antibiotic timing.

    What This Study Adds:

    Antibiotics were associated with newly diagnosed JIA in a dose- and time-dependent manner after adjusting for infection and other confounders. Antibiotics may play a role in the pathogenesis of JIA.

    Juvenile idiopathic arthritis (JIA) is the most common rheumatic diagnosis in children, but its etiology remains unclear.1 Despite the presence of known genetic risk factors, population-based studies suggest that genetics explains only 10% to 25% of disease incidence.2,3 Environmental triggers such as viral infections have been suggested,4–6 but other studies have not substantiated these findings.7–10 One study found that hospitalization for infection in the first year of life was associated with an increased risk of developing JIA.11 However, this study focused on hospital-based diagnoses and not on antibiotic use, thus limiting its interpretability.

    Disturbance of the human microbiome has been implicated in the development of chronic pediatric diseases, including inflammatory bowel disease (IBD).12,13 At least 1 category of JIA has been associated with distinct intestinal microbial populations.14 Antibiotics can alter some subjects’ intestinal microbiota for ≥6 months.15–17 Correspondingly, anaerobic antibiotic use has been associated with incident pediatric IBD.18 Another recent study suggested that childhood antibiotic exposure was associated with a subsequent diagnosis of JIA.19 Of note, this study controlled for age, gender, and geography but did not differentiate the effects of antibiotic use from the effects of infection. Furthermore, the impact of antibiotic timing was not examined in detail. The present study tested the hypothesis that antibiotics were associated with incident JIA in a large pediatric population in a dose- and time-dependent fashion after adjusting for confounding from infection and other variables.

    Methods

    Study Design and Data Source

    A nested case–control study was performed by using The Health Improvement Network (THIN), a population-representative electronic medical records database from >550 practices of general practitioners across the United Kingdom.20 This design was chosen for its computational efficiency and unbiased estimates of incidence rate ratios, including when studying common time-varying exposures and rare outcomes.21,22 Data within THIN are collected during routine medical care by using Vision software (INPS, London, United Kingdom) and are anonymized for research purposes. These data contain information on demographic characteristics, diagnoses, specialist and hospital referrals, and outpatient prescriptions. The present study included data from 1994 through 2013. THIN has been validated for several diseases in pharmacoepidemiologic research,23 including JIA.24

    Subject Selection

    Eligible subjects were aged 1 to 15 years, born after initiation of the Vision software, and registered within 3 months of birth to capture lifetime outpatient prescriptions. Cases were defined by using diagnostic Read codes (analogous to International Classification of Diseases, Ninth Revision/Tenth Revision codes) validated for JIA.24 The study period spanned from registration to the date of the first JIA code (ie, the index date). Secondary case definitions were analyzed to improve the specificity of JIA diagnosis, consisting of the JIA code (same index date) plus: (1) anti-inflammatory prescription (nonsteroidal or glucocorticoid, 2 months before to 1 year after diagnosis) or disease-modifying antirheumatic drugs (postdiagnosis); (2) rheumatology referral; and (3) anti-inflammatory/disease-modifying antirheumatic drug prescriptions and/or rheumatology visits ≥3 months after diagnosis. Children with previous IBD, immunodeficiency, or non-JIA systemic rheumatic diseases (eg, lupus, vasculitis) were excluded.

    Ten control subjects without inclusion or exclusion diagnoses were matched according to age and gender to each case subject at the index date by using incidence density sampling. To limit practice-based confounding based on general practitioners’ lack of awareness of JIA, control subjects were randomly selected from practices caring for at least 1 subject with JIA. Control subjects were not matched on practice (except sensitivity analyses) to capture variability in antibiotic prescribing across practices. Matching on practice can cause overmatching when the same prescribing physicians treat both case and control subjects.25

    Exposure and Covariate Data

    Exposures to systemic antibacterial antibiotics prescribed by general practitioners were examined, characterized according to type, date, and dose (courses or weeks prescribed). Prescriptions written on different days at any time before diagnosis were considered a new course. When course duration was unclear, the mode was imputed according to age and drug class. Additional analyses examined antibiotics categorized as antianaerobic versus non-antianaerobic or by individual antibiotic classes18 (Table 1). Antibiotics were also stratified according to the presence of enterohepatic circulation, using biliary/fecal excretion as a proxy,26–28 with the theory that such drugs might preferentially affect intestinal microbiota. Systemic nonbacterial (eg, antifungal, antiviral) antimicrobial agents were analyzed for comparison.

    View this table:
    • View inline
    • View popup
    TABLE 1

    Characteristics of the Study Population

    Potential confounders were demographic variables, comorbidities, previous infections, maternal autoimmunity, and other factors such as hospitalization (Table 1). Diagnoses including infections were identified by using Read codes. Antibiotic courses and hospitalizations within ±1 week of an infection were attributed to that infection. Outpatient visits were tabulated over 2 years starting 2.5 years before the index date, excluding 6 months before diagnosis to limit biased ascertainment of this covariate. For the same reason, outpatient visits and hospitalizations for JIA symptoms (eg, joint swelling, limp) were excluded.

    Subjects were matched with mothers by using an algorithm modified from a previous approach.29 Briefly, family relationships are not explicit in THIN due to anonymization, but deidentified household numbers are recorded. Subjects were matched with female subjects from the same household who were aged 12 to 50 years at subjects’ birth. If matches remained ambiguous, codes for pregnancy, labor/delivery, and postnatal period were identified within 270 days before to 90 days after subjects’ birth dates, and eligible maternal age was restricted to 15 to 45 years. Only subjects matched to a unique female were analyzed in models with maternal data.

    Statistical Analysis

    The association between antibiotic prescription and JIA was determined by conditional logistic regression, accounting for matching. Associations were expressed as odds ratios (ORs) with 95% confidence intervals (CIs). After unadjusted analysis, potential confounders were included in a multivariable model if associated with the outcome in univariate analysis with P < .2; they were retained if they changed the OR by ≥10% or had a P value <.05. Variables with >10% missing data were excluded from the multivariable analysis.

    Antibiotic dose models (based on number of courses or weeks prescribed) examined dose as an ordinal or continuous variable, the latter to test for trend. The effect of timing of the first and last antibiotic exposure during the study period was examined. Primary and secondary analyses were repeated based on secondary case definitions. Additional secondary analyses were performed for each antibiotic category (antianaerobic versus other) and class. To consider confounding by indication (whereby infections rather than antibiotics could be associated with JIA risk), we compared the risk of treated and untreated upper respiratory tract infections (URIs) because patients with these common conditions may or may not warrant and receive antibiotic treatment.

    Multiple sensitivity analyses were performed (Supplemental Table 5). To further consider confounding by infection, analyses compared the rate of infection between case subjects and control subjects not prescribed antibiotics. Study periods ending 4, 8, and 12 months before the index date were examined to determine whether infections closer to diagnosis were more strongly associated with JIA. To address possible confounding by local environmental factors and practice patterns, analyses were repeated after matching case subjects and control subjects according to practice along with age and gender. Protopathic bias was explored, whereby antibiotics are given for early JIA symptoms, by using as the index date the first joint symptom (eg, stiffness, limp) or rheumatology visit that preceded diagnosis (if known). Because inpatient medications are not well captured in THIN, analyses assumed that antibiotics were received with infection-related or all hospitalizations. Finally, the role of unmeasured confounding was also examined by using the rule out method; this method tests whether a theoretical confounder could nullify results over a range of covariate prevalence and associations with exposure and outcome.30

    All analyses were performed by using Stata version 12.1 (Stata Corp, College Station, TX). Hypothesis tests were 2-sided with a type I error of 0.05. P values were derived from regression models. There was no adjustment for multiple comparisons in secondary or sensitivity analyses. This study of anonymized data was exempted by the University of Pennsylvania institutional review board and was approved by THIN’s scientific review committee.

    Results

    Characteristics of the Study Population

    There were 152 cases of JIA diagnosed in 454 457 children meeting the inclusion criteria, within 3.1 million person-years of follow-up (Fig 1, Supplemental Table 6). These data yielded an incidence of 4.9 per 100 000 person-years (female subjects: 6.4 per 100 000; male subjects: 3.6 per 100 000) (Supplemental Table 7).

    FIGURE 1
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 1

    Flowchart of subject selection. The diagram displays the numbers of patients excluded from the THIN cohort and reasons for exclusion, leading to selection of case subjects with JIA and age- and gender-matched control subjects randomly selected (10:1) at the time of diagnosis.

    Because of matching, case subjects and control subjects did not differ in age or gender (Table 1). Previous autoimmunity, including psoriasis and uveitis, was more prevalent among case subjects (P = .002). Case subjects more commonly had a history of infection (P = .01) and hospitalization for infection (P = .01), and they had more infections (P = .03) than control subjects. Case subjects also had more outpatient visits (P < .001). Mothers of case subjects were nearly twice as likely to have autoimmune diseases (P < .001). Cesarean delivery may have been more common among case subjects (P = .07), but this variable had considerable missing data (37%).

    Association Between Antibiotics and JIA

    After adjustment for matching, other autoimmune conditions, and previous infection, receipt of ≥1 antibiotic prescription was associated with an increased risk of developing JIA (adjusted OR: 2.1 [95% CI: 1.2–3.5]) (Table 2). Adjustment for specific infection types (eg, URI) or number of infections did not appreciably change this association (adjusted OR range: 2.0–2.5). The magnitude of the association increased with additional antibiotic courses (test for trend: P < .001) (Table 3). Models that analyzed dose in weeks prescribed produced a similar dose response.

    View this table:
    • View inline
    • View popup
    TABLE 2

    Association of Any Antibiotic Prescription With JIA

    View this table:
    • View inline
    • View popup
    TABLE 3

    Association of Antibiotic Prescription Dose With JIA

    In terms of timing of antibiotic exposure, age of first prescription did not significantly modify the relationship between antibiotic use and JIA (test for interaction: P = .50). In contrast, timing of last exposure was important. Antibiotics prescribed within 1 year of diagnosis (and within 6 months of first joint symptom or rheumatology referral) showed the strongest association with JIA (Table 4). In contrast, untreated infections were not associated with JIA during any time period.

    View this table:
    • View inline
    • View popup
    TABLE 4

    Effect of Timing of Exposure on the Association With JIA

    Secondary Analyses

    Results of repeat analyses using secondary case definitions were similar (Tables 2 and 3). The association between antibiotics and JIA was also similar for antianaerobic and non-antianaerobic antibiotics, for drugs with and without enterohepatic circulation, and for individual drug classes, although the association for cephalosporins was weak and not significant (Supplemental Table 8). Notably, nonbacterial antimicrobial drugs lacked association with JIA. In exploring possible confounding by infections, having multiple antibiotic-treated URIs was strongly associated with JIA, but there was no association between JIA and multiple untreated URIs. An association with treated URIs persisted after excluding cases of acute otitis media, pharyngitis, and sinusitis.

    Sensitivity Analyses

    Number of infections was not associated with JIA among exposed (adjusted OR: 1.02 [95% CI: 0.98–1.05]) and unexposed (adjusted OR: 1.06 [95% CI: 0.80–1.42]) subjects. However, in an unmatched sensitivity analysis of unexposed subjects, URI was associated with JIA. This association weakened and was not significant when using an index date 4 to 12 months before JIA diagnosis.

    When control subjects were matched on practice, the association between antibiotics and JIA was similar to the original data set, if modestly stronger (Supplemental Table 9). Results were also similar when the first joint symptom or rheumatology referral was used as the index date, and when hospitalization (for infection or otherwise) was considered equivalent to an antibiotic course. Based on the strength of the association (OR: 2.1), only prevalent (20%–60%) and strong (OR: 5–10 with exposure and outcome) unmeasured confounders could explain and nullify these results, calculated by using the rule out method.30 Adjustment for noninfectious hospitalization alone and in combination with maternal autoimmunity and visits had minimal effect on the main results.

    Discussion

    Previous studies indicate that antibiotic exposure may possibly predispose children to chronic diseases, including IBD18 and JIA.19 Our study supports the hypothesis that antibiotic exposure is associated with an increased risk of developing JIA. This effect was significant after adjusting for confounders such as infection. These findings were also dose dependent, strongest within 1 year of diagnosis, specific to antibacterial antimicrobial agents, and robust to numerous sensitivity analyses. Together, these results suggest a possible role for antibiotics in JIA pathogenesis. This public health finding is potentially important, considering that approximately one-quarter of antibiotics prescribed for children, and an estimated one-half of antibiotics for acute respiratory infections, may be unnecessary and potentially avoidable.31,32

    The human microbiome plays important roles in immune regulation and self-tolerance.33 Disturbance of the intestinal microbiome has been linked to several autoimmune diseases, including IBD,34,35 rheumatoid arthritis,36–40 and at least 1 category of JIA.14 After antibiotic treatment, commensal microbial populations often recover within ∼3 months, including in young children.17,41 However, rates of microbial recovery are variable, and incomplete recovery of certain taxa may persist for ≥6 months, particularly after repeated antibiotic exposures.15–17,42 Our finding that antibiotic exposure is most strongly associated with JIA within 1 year of diagnosis (and 6 months of first symptom/referral) supports the hypothesis that antibiotic-induced microbiome dysregulation could precipitate JIA in children predisposed to this disease.

    In addition to a causal relationship, alternative explanations for this association are protopathic bias (treatment of early JIA symptoms with antibiotics) and confounding from infection. We found no evidence of protopathic bias in a sensitivity analysis that used first joint symptom or rheumatology referral as the index date. Unfortunately, we could not study or exclude subjects with systemic JIA, who present with symptoms including fever and rash that might initially be confused with infection and treated with antibiotics. However, systemic JIA usually presents acutely and only comprises ∼5% to 10% of all JIA diagnoses.43 This JIA category, therefore, is unlikely to fully explain the association with antibiotics, including exposures 6 to 12 months before diagnosis.

    Confounding from infection could occur if infections triggered JIA or if an inherited or acquired immunodeficiency preceded the diagnosis of JIA. We found a significant association between URIs and JIA among unexposed subjects in the months preceding diagnosis. For some subjects, this finding could represent an early predisposition to infection, a short-term infectious trigger, a process exacerbating subclinical arthritis, or an event that merely brought arthritis symptoms to medical attention. Antibiotic-untreated infections can also precipitate changes in children’s microbiota.41 JIA has rarely been reported in association with a definable immunodeficiency,44 but children diagnosed with JIA are at higher risk for serious infection independent of disease treatment.45 In our study, case subjects had more office visits than control subjects and were more likely to be hospitalized for infection. It is unclear whether more severe infections led to more antibiotics, which then triggered autoimmunity in susceptible subjects, or whether JIA-associated immune dysfunction caused more severe illnesses beforehand, for which antibiotics were a marker. Because office visits and hospitalizations could be on the causal pathway between antibiotics and JIA, we did not adjust for these variables in the primary analyses. Of note, the lack of association of JIA with nonbacterial antimicrobial agents argues against the immunodeficiency hypothesis. Indeed, these findings, and the stronger association of JIA with antibiotic-treated URIs than with untreated URIs, support a causal model for antibiotics.

    Our study has several strengths. Outpatient prescription data are comprehensive in THIN, and most antibiotics in general pediatrics are prescribed in the outpatient setting, ensuring near complete capture of antibiotic exposure in these children followed up from early infancy. The failure of some subjects to take some or all of the prescribed medication would likely bias results toward the null, suggesting that our study may underestimate the true effect. Although inpatient prescription data were not available, models assuming inpatient antibiotic exposure were similar. Infections were important confounders in the relationship between antibiotics and JIA, and timing of last antibiotic exposure proved important. Our analyses incorporating these factors made this study unique compared with an earlier report.19 JIA itself has previously been validated with 86% positive predictive value.24 The incidence (overall and gender-specific) of JIA in our cohort was similar to earlier published estimates from other western European countries using current classification criteria.46,47 Secondary case definitions designed to increase the specificity of JIA diagnoses yielded similar results. Finally, multiple sensitivity analyses were consistent and robust to a wide range of assumptions.

    This study has several limitations. Although JIA has been validated, specific JIA categories have not been validated and are usually unspecified in THIN. This absence made it difficult to discern whether antibiotics were associated only with particular JIA categories. If this association were category-specific, then the true effect could be larger for certain forms of JIA and null for others. Similarly, race and ethnicity correspond to differences in JIA presentation48 but are poorly captured by THIN data. The study’s inclusion of children registered early in life also identified a relatively young cohort. This design limited the study’s generalizability to older children and adolescents, and compromised our ability to study the interaction between age and antibiotic exposure on JIA risk, including age of diagnosis. In addition, we could not detect substantial differences across antibiotic classes, as was previously shown for pediatric IBD18 and JIA in another study that reported relatively greater risk for cephalosporins and clindamycin19; our study was not powered to address this specific issue. Finally, despite our efforts to account for infection and our many analyses implicating antibiotics in the development of JIA, we cannot definitively rule out residual confounding from infections.

    Conclusions

    The present study found that treatment with antibiotics was associated with the development of JIA in a large general pediatric population. This relationship was dose dependent, strongest within 1 year of diagnosis, specific for antibacterial agents, persisted after adjustment for infection, and was robust to numerous assumptions. These findings suggest a potential role for antibiotics in the pathogenesis of JIA, perhaps mediated through changes in the microbiome. If this association is causal, antibiotics could be considered a potentially modifiable risk factor for JIA, especially in light of the overprescribing of antibiotics to children, particularly for respiratory tract infections. Children with JIA may also be at risk for more infections before diagnosis due to immune dysfunction, and a causal role for infections remains a possibility. Further research is necessary to confirm these findings in other populations; to determine whether this association depends on age, JIA category, and antibiotic drug class; and to investigate underlying mechanisms.

    Acknowledgment

    The authors thank Molly Collins, MD, for her critical review of the manuscript.

    Footnotes

      • Accepted May 11, 2015.
    • Address correspondence to Daniel B. Horton, MD, Office of the Chancellor, Rutgers Biomedical & Health Sciences Child Health Institute of New Jersey, 4th floor, 89 French St, New Brunswick, NJ 08901. E-mail: daniel.horton{at}rutgers.edu
    • Dr Horton conceptualized and designed the study, conducted the analyses, and drafted the initial manuscript; Drs Scott and Rose provided input in study design and critically reviewed the manuscript; Dr Haynes provided input in study design, assisted with data extraction, and critically reviewed the manuscript; and Drs Lewis, Putt, and Strom provided input in study design, provided guidance on analyses, and critically reviewed the manuscript. All authors approved the final manuscript as submitted.

    • Dr Horton's current affiliation is Rutgers Biomedical and Health Sciences, New Brunswick, New Jersey.

    • FINANCIAL DISCLOSURE: The authors have indicated they have no financial relationships relevant to this article to disclose.

    • FUNDING: All phases of this study were supported by grants from the National Institutes of Health (NIH): NIH NRSA T32-GM075766 Clinical Pharmacoepidemiology Training Grant (Dr Strom [Principal Investigator], Dr Horton); NIH NRSA F32-AR066461 Individual Fellowship (Dr Horton); NIH K08-DK095951 (Dr Scott); and NIH K24-DK078228 (Dr Lewis). Funded by the National Institutes of Health (NIH).

    • POTENTIAL CONFLICT OF INTEREST: Dr Rose served on the data and safety monitoring committee for Bristol-Myers Squibb for a trial of the pediatric formulation of abatacept for the treatment of juvenile idiopathic arthritis, and Dr Strom has consulted for the following antibiotic manufacturers (on matters unrelated to the article): Abbott, AbbVie, AstraZeneca, Bayer, Bristol-Myers Squibb, GlaxoSmithKline, Lundbeck, Roche, Sanofi, Takeda, and Teva. Dr Lewis has served as a consultant for the following antibiotic manufacturers (on matters completely unrelated to this manuscript): AbbVie, AstraZeneca, Janssen Pharmaceuticals, Medimmune, Merck, Takeda, Shire. He has served on a Data and Safety Monitoring Board for clinical trials (unrelated to antibiotics) sponsored by Pfizer, another antibiotic manufacturer. He has also served as a consultant for Nestle Health Science and Rebiotix, companies studying therapies for intestinal health (on matters completely unrelated to this manuscript). The other authors have indicated they have no potential conflicts of interest to disclose.

    • COMPANION PAPER: A companion to this article can be found on page e492, online at www.pediatrics.org/cgi/doi/10.1542/peds.2015-1296.

    References

    1. ↵
      1. Ravelli A,
      2. Martini A
      . Juvenile idiopathic arthritis. Lancet. 2007;369(9563):767–778pmid:17336654
      OpenUrlCrossRefPubMed
    2. ↵
      1. Prahalad S,
      2. Zeft AS,
      3. Pimentel R,
      4. et al
      . Quantification of the familial contribution to juvenile idiopathic arthritis. Arthritis Rheum. 2010;62(8):2525–2529pmid:20506132
      OpenUrlCrossRefPubMed
    3. ↵
      1. Savolainen A,
      2. Saila H,
      3. Kotaniemi K,
      4. Kaipianen-Seppanen O,
      5. Leirisalo-Repo M,
      6. Aho K
      . Magnitude of the genetic component in juvenile idiopathic arthritis. Ann Rheum Dis. 2000;59(12):1001pmid:11153478
      OpenUrlFREE Full Text
    4. ↵
      1. Gonzalez B,
      2. Larrañaga C,
      3. León O,
      4. et al
      . Parvovirus B19 may have a role in the pathogenesis of juvenile idiopathic arthritis. J Rheumatol. 2007;34(6):1336–1340pmid:17477467
      OpenUrlAbstract/FREE Full Text
      1. Massa M,
      2. Mazzoli F,
      3. Pignatti P,
      4. et al
      . Proinflammatory responses to self HLA epitopes are triggered by molecular mimicry to Epstein-Barr virus proteins in oligoarticular juvenile idiopathic arthritis. Arthritis Rheum. 2002;46(10):2721–2729pmid:12384932
      OpenUrlCrossRefPubMed
    5. ↵
      1. Pritchard MH,
      2. Matthews N,
      3. Munro J
      . Antibodies to influenza A in a cluster of children with juvenile chronic arthritis. Br J Rheumatol. 1988;27(3):176–180pmid:3378122
      OpenUrlAbstract/FREE Full Text
    6. ↵
      1. Feldman BM,
      2. Birdi N,
      3. Boone JE,
      4. et al
      . Seasonal onset of systemic-onset juvenile rheumatoid arthritis. J Pediatr. 1996;129(4):513–518pmid:8859257
      OpenUrlCrossRefPubMed
      1. Söderlund M,
      2. von Essen R,
      3. Haapasaari J,
      4. Kiistala U,
      5. Kiviluoto O,
      6. Hedman K
      . Persistence of parvovirus B19 DNA in synovial membranes of young patients with and without chronic arthropathy. Lancet. 1997;349(9058):1063–1065pmid:9107245
      OpenUrlCrossRefPubMed
      1. Tsai YT,
      2. Chiang BL,
      3. Kao YF,
      4. Hsieh KH
      . Detection of Epstein-Barr virus and cytomegalovirus genome in white blood cells from patients with juvenile rheumatoid arthritis and childhood systemic lupus erythematosus. Int Arch Allergy Immunol. 1995;106(3):235–240pmid:7888786
      OpenUrlCrossRefPubMed
    7. ↵
      1. Weissbrich B,
      2. Süss-Fröhlich Y,
      3. Girschick HJ
      . Seroprevalence of parvovirus B19 IgG in children affected by juvenile idiopathic arthritis. Arthritis Res Ther. 2007;9(4):R82pmid:17760961
      OpenUrlCrossRefPubMed
    8. ↵
      1. Carlens C,
      2. Jacobsson L,
      3. Brandt L,
      4. Cnattingius S,
      5. Stephansson O,
      6. Askling J
      . Perinatal characteristics, early life infections and later risk of rheumatoid arthritis and juvenile idiopathic arthritis. Ann Rheum Dis. 2009;68(7):1159–1164pmid:18957482
      OpenUrlAbstract/FREE Full Text
    9. ↵
      1. Conte MP,
      2. Schippa S,
      3. Zamboni I,
      4. et al
      . Gut-associated bacterial microbiota in paediatric patients with inflammatory bowel disease. Gut. 2006;55(12):1760–1767pmid:16648155
      OpenUrlAbstract/FREE Full Text
    10. ↵
      Schwiertz A, Jacobi M, Frick JS, Richter M, Rusch K, Köhler H. Microbiota in pediatric inflammatory bowel disease. J Pediatr. 2010;157(2):240–244.e1
    11. ↵
      1. Stoll ML,
      2. Kumar R,
      3. Morrow CD,
      4. et al
      . Altered microbiota associated with abnormal humoral immune responses to commensal organisms in enthesitis-related arthritis. Arthritis Res Ther. 2014;16(6):486pmid:25434931
      OpenUrlCrossRefPubMed
    12. ↵
      1. Dethlefsen L,
      2. Huse S,
      3. Sogin ML,
      4. Relman DA
      . The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing. PLoS Biol. 2008;6(11):e280pmid:19018661
      OpenUrlCrossRefPubMed
      1. Dethlefsen L,
      2. Relman DA
      . Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation. Proc Natl Acad Sci U S A. 2011;108(suppl 1):4554–4561pmid:20847294
      OpenUrlAbstract/FREE Full Text
    13. ↵
      1. Jernberg C,
      2. Löfmark S,
      3. Edlund C,
      4. Jansson JK
      . Long-term ecological impacts of antibiotic administration on the human intestinal microbiota. ISME J. 2007;1(1):56–66pmid:18043614
      OpenUrlCrossRefPubMed
    14. ↵
      1. Kronman MP,
      2. Zaoutis TE,
      3. Haynes K,
      4. Feng R,
      5. Coffin SE
      . Antibiotic exposure and IBD development among children: a population-based cohort study. Pediatrics. 2012;130(4). Available at: www.pediatrics.org/cgi/content/full/130/4/e794pmid:23008454
      OpenUrlAbstract/FREE Full Text
    15. ↵
      1. Arvonen M,
      2. Virta LJ,
      3. Pokka T,
      4. Kröger L,
      5. Vähäsalo P
      . Repeated exposure to antibiotics in infancy: a predisposing factor for juvenile idiopathic arthritis or a sign of this group’s greater susceptibility to infections? J Rheumatol. 2015;42(3):521–526pmid:25320218
      OpenUrlAbstract/FREE Full Text
    16. ↵
      1. Blak BT,
      2. Thompson M,
      3. Dattani H,
      4. Bourke A
      . Generalisability of The Health Improvement Network (THIN) database: demographics, chronic disease prevalence and mortality rates. Inform Prim Care. 2011;19(4):251–255pmid:22828580
      OpenUrlPubMed
    17. ↵
      1. Austin PC,
      2. Anderson GM,
      3. Cigsar C,
      4. Gruneir A
      . Comparing the cohort design and the nested case-control design in the presence of both time-invariant and time-dependent treatment and competing risks: bias and precision. Pharmacoepidemiol Drug Saf. 2012;21(7):714–724pmid:22653805
      OpenUrlCrossRefPubMed
    18. ↵
      1. Essebag V,
      2. Platt RW,
      3. Abrahamowicz M,
      4. Pilote L
      . Comparison of nested case-control and survival analysis methodologies for analysis of time-dependent exposure. BMC Med Res Methodol. 2005;5(1):5pmid:15670334
      OpenUrlCrossRefPubMed
    19. ↵
      1. Lewis JD,
      2. Schinnar R,
      3. Bilker WB,
      4. Wang X,
      5. Strom BL
      . Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research. Pharmacoepidemiol Drug Saf. 2007;16(4):393–401pmid:17066486
      OpenUrlCrossRefPubMed
    20. ↵
      1. Thomas SL,
      2. Edwards CJ,
      3. Smeeth L,
      4. Cooper C,
      5. Hall AJ
      . How accurate are diagnoses for rheumatoid arthritis and juvenile idiopathic arthritis in the general practice research database? Arthritis Rheum. 2008;59(9):1314–1321pmid:18759262
      OpenUrlCrossRefPubMed
    21. ↵
      1. Walker AM
      . Matching on provider is risky. J Clin Epidemiol. 2013;66(suppl 8):S65–S68pmid:23849156
      OpenUrlCrossRefPubMed
    22. ↵
      1. Roberts MS,
      2. Magnusson BM,
      3. Burczynski FJ,
      4. Weiss M
      . Enterohepatic circulation: physiological, pharmacokinetic and clinical implications. Clin Pharmacokinet. 2002;41(10):751–790pmid:12162761
      OpenUrlCrossRefPubMed
    23. Sweetman S, ed. Martindale: The Complete Drug Reference. London, United Kingdom: Pharmaceutical Press. Available at: www.medicinescomplete.com. Accessed February 8, 2015
    24. ↵
      Micromedex 2.0 (electronic version). Greenwood Village, CO: Truven Health Analytics. Available at: http://micromedex.com/. Accessed February 8, 2015
    25. ↵
      1. Hardy JR,
      2. Holford TR,
      3. Hall GC,
      4. Bracken MB
      . Strategies for identifying pregnancies in the automated medical records of the General Practice Research Database. Pharmacoepidemiol Drug Saf. 2004;13(11):749–759pmid:15386720
      OpenUrlCrossRefPubMed
    26. ↵
      1. Schneeweiss S
      . Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics. Pharmacoepidemiol Drug Saf. 2006;15(5):291–303pmid:16447304
      OpenUrlCrossRefPubMed
    27. ↵
      1. Hersh AL,
      2. Shapiro DJ,
      3. Pavia AT,
      4. Shah SS
      . Antibiotic prescribing in ambulatory pediatrics in the United States. Pediatrics. 2011;128(6):1053–1061pmid:22065263
      OpenUrlAbstract/FREE Full Text
    28. ↵
      1. Kronman MP,
      2. Zhou C,
      3. Mangione-Smith R
      . Bacterial prevalence and antimicrobial prescribing trends for acute respiratory tract infections. Pediatrics. 2014;134(4). Available at: www.pediatrics.org/cgi/content/full/130/4/e956pmid:25225144
      OpenUrlAbstract/FREE Full Text
    29. ↵
      1. Maynard CL,
      2. Elson CO,
      3. Hatton RD,
      4. Weaver CT
      . Reciprocal interactions of the intestinal microbiota and immune system. Nature. 2012;489(7415):231–241pmid:22972296
      OpenUrlCrossRefPubMed
    30. ↵
      1. Kang S,
      2. Denman SE,
      3. Morrison M,
      4. et al
      . Dysbiosis of fecal microbiota in Crohn’s disease patients as revealed by a custom phylogenetic microarray. Inflamm Bowel Dis. 2010;16(12):2034–2042pmid:20848492
      OpenUrlCrossRefPubMed
    31. ↵
      1. Lepage P,
      2. Häsler R,
      3. Spehlmann ME,
      4. et al
      . Twin study indicates loss of interaction between microbiota and mucosa of patients with ulcerative colitis. Gastroenterology. 2011;141(1):227–236pmid:21621540
      OpenUrlCrossRefPubMed
    32. ↵
      1. Scher JU,
      2. Sczesnak A,
      3. Longman RS,
      4. et al
      . Expansion of intestinal Prevotella copri correlates with enhanced susceptibility to arthritis. eLife. 2013;2:e01202pmid:24192039
      OpenUrlAbstract/FREE Full Text
      1. Potikuri D,
      2. Dannana KC,
      3. Kanchinadam S,
      4. et al
      . Periodontal disease is significantly higher in non-smoking treatment-naive rheumatoid arthritis patients: results from a case-control study. Ann Rheum Dis. 2012;71(9):1541–1544pmid:22875903
      OpenUrlAbstract/FREE Full Text
      1. Wegner N,
      2. Wait R,
      3. Sroka A,
      4. et al
      . Peptidylarginine deiminase from Porphyromonas gingivalis citrullinates human fibrinogen and α-enolase: implications for autoimmunity in rheumatoid arthritis. Arthritis Rheum. 2010;62(9):2662–2672pmid:20506214
      OpenUrlCrossRefPubMed
      1. Savioli C,
      2. Ribeiro AC,
      3. Fabri GM,
      4. et al
      . Persistent periodontal disease hampers anti-tumor necrosis factor treatment response in rheumatoid arthritis. J Clin Rheumatol. 2012;18(4):180–184pmid:22647860
      OpenUrlPubMed
    33. ↵
      1. Mikuls TR,
      2. Payne JB,
      3. Yu F,
      4. et al
      . Periodontitis and Porphyromonas gingivalis in patients with rheumatoid arthritis. Arthritis Rheum (Munch). 2014;66(5):1090–1100pmid:24782175
      OpenUrlCrossRefPubMed
    34. ↵
      1. Koenig JE,
      2. Spor A,
      3. Scalfone N,
      4. et al
      . Succession of microbial consortia in the developing infant gut microbiome. Proc Natl Acad Sci U S A. 2011;108(suppl 1):4578–4585pmid:20668239
      OpenUrlAbstract/FREE Full Text
    35. ↵
      1. Jakobsson HE,
      2. Jernberg C,
      3. Andersson AF,
      4. Sjölund-Karlsson M,
      5. Jansson JK,
      6. Engstrand L
      . Short-term antibiotic treatment has differing long-term impacts on the human throat and gut microbiome. PLoS One. 2010;5(3):e9836pmid:20352091
      OpenUrlCrossRefPubMed
    36. ↵
      1. Thierry S,
      2. Fautrel B,
      3. Lemelle I,
      4. Guillemin F
      . Prevalence and incidence of juvenile idiopathic arthritis: a systematic review. Joint Bone Spine. 2014;81(2):112–117pmid:24210707
      OpenUrlCrossRefPubMed
    37. ↵
      1. Uluhan A,
      2. Sager D,
      3. Jasin HE
      . Juvenile rheumatoid arthritis and common variable hypogammaglobulinemia. J Rheumatol. 1998;25(6):1205–1210pmid:9632087
      OpenUrlPubMed
    38. ↵
      1. Beukelman T,
      2. Xie F,
      3. Chen L,
      4. et al.,
      5. SABER Collaboration
      . Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum. 2012;64(8):2773–2780pmid:22569881
      OpenUrlCrossRefPubMed
    39. ↵
      1. Modesto C,
      2. Antón J,
      3. Rodriguez B,
      4. et al
      . Incidence and prevalence of juvenile idiopathic arthritis in Catalonia (Spain). Scand J Rheumatol. 2010;39(6):472–479pmid:20858139
      OpenUrlCrossRefPubMed
    40. ↵
      1. Danner S,
      2. Sordet C,
      3. Terzic J,
      4. et al
      . Epidemiology of juvenile idiopathic arthritis in Alsace, France. J Rheumatol. 2006;33(7):1377–1381pmid:16821272
      OpenUrlAbstract/FREE Full Text
    41. ↵
      1. Oen KG,
      2. Cheang M
      . Epidemiology of chronic arthritis in childhood. Semin Arthritis Rheum. 1996;26(3):575–591pmid:8989803
      OpenUrlCrossRefPubMed
    • Copyright © 2015 by the American Academy of Pediatrics
    PreviousNext
    Back to top

    Advertising Disclaimer »

    In this issue

    Pediatrics
    Vol. 136, Issue 2
    1 Aug 2015
    • Table of Contents
    • Index by author
    View this article with LENS
    PreviousNext
    Email Article

    Thank you for your interest in spreading the word on American Academy of Pediatrics.

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    Antibiotic Exposure and Juvenile Idiopathic Arthritis: A Case–Control Study
    (Your Name) has sent you a message from American Academy of Pediatrics
    (Your Name) thought you would like to see the American Academy of Pediatrics web site.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Request Permissions
    Article Alerts
    Log in
    You will be redirected to aap.org to login or to create your account.
    Or Sign In to Email Alerts with your Email Address
    Citation Tools
    Antibiotic Exposure and Juvenile Idiopathic Arthritis: A Case–Control Study
    Daniel B. Horton, Frank I. Scott, Kevin Haynes, Mary E. Putt, Carlos D. Rose, James D. Lewis, Brian L. Strom
    Pediatrics Aug 2015, 136 (2) e333-e343; DOI: 10.1542/peds.2015-0036

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
    Share
    Antibiotic Exposure and Juvenile Idiopathic Arthritis: A Case–Control Study
    Daniel B. Horton, Frank I. Scott, Kevin Haynes, Mary E. Putt, Carlos D. Rose, James D. Lewis, Brian L. Strom
    Pediatrics Aug 2015, 136 (2) e333-e343; DOI: 10.1542/peds.2015-0036
    del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
    Print
    Download PDF
    Insight Alerts
    • Table of Contents

    Jump to section

    • Article
      • Abstract
      • Methods
      • Results
      • Discussion
      • Conclusions
      • Acknowledgment
      • Footnotes
      • References
    • Figures & Data
    • Supplemental
    • Info & Metrics
    • Comments

    Related Articles

    • PubMed
    • Google Scholar

    Cited By...

    • Abuse of Antibiotics in Perinatology: Negative Impact for Health and the Economy
    • Pediatric Antibiotic-refractory Lyme Arthritis: A Multicenter Case-control Study
    • Advances in optimizing the prescription of antibiotics in outpatient settings
    • Update on Pediatric Overuse
    • Choosing Wrong
    • Google Scholar

    More in this TOC Section

    • Verbal Autopsies for Out-of-Hospital Infant Deaths in Zambia
    • Uncertainty at the Limits of Viability: A Qualitative Study of Antenatal Consultations
    • Evaluation of an Emergency Department High-risk Bruising Screening Protocol
    Show more Article

    Similar Articles

    Subjects

    • Rheumatology/Musculoskeletal Disorders
      • Rheumatology/Musculoskeletal Disorders
    • Infectious Disease
      • Infectious Disease
      • Epidemiology
    • Journal Info
    • Editorial Board
    • Editorial Policies
    • Overview
    • Licensing Information
    • Authors/Reviewers
    • Author Guidelines
    • Submit My Manuscript
    • Open Access
    • Reviewer Guidelines
    • Librarians
    • Institutional Subscriptions
    • Usage Stats
    • Support
    • Contact Us
    • Subscribe
    • Resources
    • Media Kit
    • About
    • International Access
    • Terms of Use
    • Privacy Statement
    • FAQ
    • AAP.org
    • shopAAP
    • Follow American Academy of Pediatrics on Instagram
    • Visit American Academy of Pediatrics on Facebook
    • Follow American Academy of Pediatrics on Twitter
    • Follow American Academy of Pediatrics on Youtube
    • RSS
    American Academy of Pediatrics

    © 2021 American Academy of Pediatrics